Faron says new data reinforces promise of bone marrow cancer drug
(Alliance News) - Faron Pharmaceuticals Ltd on Monday said updated biomarker data strengthened the clinical profile of bexmarilimab, its lead treatment for myelodysplastic syndrome. Read More